Greenwich LifeSciences's common stock is $15K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company). Positive growth indicates new issuance/dilution; negative growth indicates reductions/buybacks.
As of the most recent data (June 2026), GLSI shows a common stock of $15K. That compares with $13K in the prior-year period — up 8.9% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, GLSI's common stock is now $15K (was $13K) — a 8.9% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Greenwich LifeSciences is outperforming or lagging.
Tracking GLSI's common stock over time shows whether Greenwich LifeSciences is scaling, shrinking, or reshaping that part of the business. The current reading is $15K That compares with $13K in the prior-year period — up 8.9% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this common stock page, Stockcircle has Greenwich LifeSciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect common stock (currently $15K) with ownership activity and broader fundamentals.
Greenwich LifeSciences's common stock is $15K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.